Last updated: 2026-09-16 09:45:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
RenovoRx, Inc. (RNXT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.75, with a market capitalisation of $76.27M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.70 to $2.59. This page covers its latest market performance, valuation, price trends and company information.
$76.27M | |
$1.75 | |
$16.74 | |
$0.53 | |
$1.72 | |
22.00 | |
686.41K | |
-- | |
$2.59 | |
$0.70 | |
-- | |
-- |
RenovoRx, Inc. (RNXT) is trading at $1.75 in pre-market trading as of 2026-09-16 09:26:00, up 1.74% ($0.03) from the previous close of $1.72
Pre-market trading shows how investors are pricing RNXT before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, RenovoRx, Inc. (RNXT) moved from $2.39 to $1.75, representing a decline of 26.78% ($0.64).
The stock traded between $1.60 and $2.54 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.35 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 55.5%
RNXT is currently trading at $1.75, placing it 55.5% of the way from its 52-week low of $0.70 to its 52-week high of $2.59. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 17 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of RenovoRx, Inc. (RNXT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.